| Reinhardt, Dirk |
| Recruiting | 2 | 89 | Europe, RoW | Mylotarg, GO, Arsenic Trioxide, ATO, All-trans retinoic acid, ATRA | Associazione Italiana Ematologia Oncologia Pediatrica, AIEOP | Acute Promyelocytic Leukemia | 10/25 | 10/27 | | |
| Recruiting | 1/2 | 413 | Europe, Canada, US, RoW | revumenib, SNDX-5613, cobicistat | Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 12/27 | 12/27 | | |
|
|
|
|
|
|
|
|
|
| Recruiting | 1/2 | 30 | Europe | Peptide vaccine IPX | University Hospital Tuebingen, Deutsches Konsortium fürTranslationale Krebsforschung (DKTK), Cooperative Ewing Sarkom Studiengruppe, Cooperative Weichteilsarkom Study Group | Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma | 06/27 | 09/27 | | |
NCT04238819: A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma |
|
|
| Active, not recruiting | 1/2 | 117 | Europe, Japan, US, RoW | Abemaciclib, LY2835219, Irinotecan, Temozolomide, Dinutuximab, GM-CSF | Eli Lilly and Company | Relapsed Solid Tumor, Refractory Solid Tumor | 03/24 | 04/25 | | |
HEM-iSMART D, NCT05658640: HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies |
|
|
| Recruiting | 1/2 | 26 | Europe, RoW | Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy | Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer | Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | 04/29 | 04/29 | | |
| Schuler, Martin |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
| Recruiting | 2 | 90 | Europe | Nivolumab 10 MG/ML Intravenous Solution, Relatlimab 10 MG/ML Intravenous Solution | University Hospital, Essen | NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I | 03/25 | 06/25 | | |
|
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing |
|
|
| Recruiting | 2 | 35 | Europe | Atezolizumab, Tecentriq, Tiragolumab, no other name available | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG | Non-small Cell Lung Cancer | 11/29 | 02/30 | | |
| Active, not recruiting | 1/2 | 274 | Europe | visugromab (CTL-002) | CatalYm GmbH, CatalYm GmbH | Solid Tumor, Adult | 10/25 | 10/27 | | |
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors |
|
|
| Recruiting | 1 | 530 | Europe, Canada, Japan, US | LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil | Eli Lilly and Company, Loxo Oncology, Inc. | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer | 03/29 | 03/29 | | |
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation |
|
|
| Active, not recruiting | N/A | 850 | Europe | DigiNet intervention | University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden | Non-small Cell Lung Cancer Stage IV | 03/25 | 03/25 | | |
| Zeller, Thomas |
| Completed | 3 | 440 | Europe, Canada, Japan, US, RoW | RANGER™ Paclitaxel Coated Balloon, Percutaneous Transluminal Angioplasty (PTA), Paclitaxel, Standard Balloon Angioplasty | Boston Scientific Corporation | Peripheral Artery Disease, Atherosclerosis, Artery Diseases, Peripheral, Plaque, Atherosclerotic, Occlusive Arterial Disease | 11/19 | 10/23 | | |
ARIVA, NCT04128956: Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS |
|
|
| Terminated | 2 | 172 | Europe | Aspirin 100mg, Aspirin | University of Zurich, University Hospital Heidelberg, Medical University of Vienna, RWTH Aachen University, Klinikum Arnsberg, University Hospital Freiburg | Venous Thromboses, Stent Stenosis | 02/24 | 02/24 | | |
XPEDITE, NCT02936622: Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses |
|
|
| Completed | N/A | 176 | Europe, RoW | Zilver® Paclitaxel-Eluting Peripheral Stent, Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating, Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating | Cook Group Incorporated | Peripheral Arterial Disease (PAD) | 04/19 | 10/23 | | |
| Completed | N/A | 499 | Europe, RoW | Stellarex 0.035" Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB), CVI Paclitaxel-Coated PTA Balloon Catheter | Spectranetics Corporation | Peripheral Arterial Disease | 08/20 | 08/22 | | |
HEAL, NCT04110327: An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects with Peripheral Arterial Disease |
|
|
| Recruiting | N/A | 300 | Europe | MicroStent | Micro Medical Solution, Inc. | Peripheral Arterial Disease, Critical Lower Limb Ischemia | 12/26 | 12/28 | | |
| Recruiting | N/A | 376 | Europe, US, RoW | SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA, Cordis Corporation | Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities | 06/27 | 07/29 | | |
| Recruiting | N/A | 288 | US | PCB, AcoArt Litos PCB, PTA | Acotec Scientific Co., Ltd | Chronic Limb-Threatening Ischemia | 12/31 | 02/32 | | |
| Recruiting | N/A | 300 | Europe, US, RoW | SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA, Cordis Corporation | Peripheral Arterial Disease, Superficial Femoral Artery Stenosis | 08/25 | 12/29 | | |
| Active, not recruiting | N/A | 333 | Europe, US, RoW | Chocolate Touch, Chocolate Touch™ Paclitaxel Coated Balloon Catheter, Lutonix Drug Coated Balloon, LUTONIX® 035 Drug Coated Balloon Catheter | TriReme Medical, LLC | Peripheral Artery Disease (PAD), Ischemia, Intermittent Claudication | 06/25 | 12/26 | | |
LIMES, NCT04772300: Trial to Assess the Safety and Efficacy of Sirolimus-Coated Balloon vs. Uncoated Standard Angioplasty for the Treatment of Below-the-knee Peripheral Arterial Disease |
|
|
| Recruiting | N/A | 230 | Europe | Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter, Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA) | Jena University Hospital, Concept Medical Inc., Vascuscience, CoreLab Black Forest, Center for Clinical Studies, University Hospital Jena | Peripheral Artery Disease | 12/27 | 09/28 | | |
| Recruiting | N/A | 3000 | Europe, RoW | The Paradise Ultrasound Renal Denervation System | ReCor Medical, Inc. | Hypertension | 12/30 | 12/31 | | |
| Rassaf, Tienush |
| Recruiting | 4 | 72 | Europe | Heart failure medication, Placebo | University Hospital, Essen | Pre-terminal Cancer | 05/24 | 10/24 | | |
| Recruiting | 2/3 | 130 | Europe | Mycophenolate Mofetil, MMF, Prednisolone, Mycophenolate Mofetil Placebo, MMF Placebo, Prednisolone Placebo | LMU Klinikum, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Technical University of Munich, Charite University, Berlin, Germany, University Hospital, Essen, University Hospital Erlangen, University Hospital Tuebingen | Inflammatory Cardiomyopathy | 03/27 | 03/28 | | |
| Recruiting | N/A | 40 | Europe | Dietary Nitrate, Control | University Hospital, Essen | Erectile Dysfunction | 06/21 | 08/21 | | |
NCT04183660: A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial |
|
|
| Recruiting | N/A | 60 | Europe | MOBYBOX System | Hemovent GmbH, seleon GmbH | Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure | 04/25 | 12/25 | | |
NCT05447052: The Biomimetic Stent and Vascular Functions Study |
|
|
| Recruiting | N/A | 70 | Europe | Bio-MIMICS 3D Stent, Innova Stent | University Hospital, Essen | Peripheral Arterial Disease | 04/24 | 04/25 | | |
| Completed | N/A | 30 | Europe | Nitrate, Control | University Hospital, Essen | Cardiovascular Health | 06/24 | 06/24 | | |
| Recruiting | N/A | 1000 | Europe | Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System | Edwards Lifesciences | Mitral Regurgitation, Mitral Insufficiency | 12/25 | 03/31 | | |
| Completed | N/A | 60 | Europe | Standard of care treatment | University Hospital, Essen | Microbial Colonization, Coronary Artery Disease, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Arterial Disease, Critical Limb Ischemia | 02/24 | 04/24 | | |
| Recruiting | N/A | 55000 | Europe | | University Hospital, Essen | Coronary Artery Disease | 12/26 | 06/27 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
NCT05450042: Vascular Effects Through Sirolimus vs. Paclitaxel DCB Implantation |
|
|
| Recruiting | N/A | 70 | Europe | SELUTION SLR DCB, Paclitaxel DCB | University Hospital, Essen | Peripheral Arterial Disease, Flow-mediated Dilation, Drug Eluting Balloon, Infrainguinal Peripheral Arterial Disease | 04/24 | 04/24 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Recruiting | N/A | 360 | Europe | Transcatheter tricuspid valve treatment (TTVT) | LMU Klinikum, Heart and Diabetes Center North Rhine-Westphalia, University Medical Center Mainz, Heart Center Leipzig - University Hospital, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), University of Leipzig | Heart Failure Attributable to Severe Tricuspid Regurgitation | 03/26 | 03/27 | | |
| Recruiting | N/A | 1054 | Europe | measurement of FFR, measurement of Pd/Pa | Helios Health Institute GmbH, Heart Center Leipzig - University Hospital | Coronary Artery Disease, Coronary Artery Stenoses | 05/26 | 11/26 | | |
RIP-HIGH, NCT04844931: Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction |
|
|
| Active, not recruiting | N/A | 250 | Europe | RIC + PostC + Standard PCI, Standard PCI | Helios Health Institute GmbH, Heart Center Leipzig - University Hospital | ST Elevation Myocardial Infarction | 12/25 | 07/30 | | |
| Recruiting | N/A | 3390 | Europe | Culprit-lesion revascularization, Culprit-lesion PCI, Non-culprit-lesion revascularization, multivessel PCI | Leipzig Heart Science gGmbH, Heart Center Leipzig at University of Leipzig, German Federal Ministry of Education and Research, IHF GmbH - Institut für Herzinfarktforschung, Stiftung IHF - Institut für Herzinfarktforschung | Non-ST-elevation Myocardial Infarction, Multivessel Coronary Artery Disease | 01/27 | 07/27 | | |
| Köhrmann, Martin |
| Recruiting | 2/3 | 200 | Europe, Canada, US | Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device, EmboTrap III, Initial medical management (iMM) | Emory University, University of Calgary, University of Cincinnati, Heidelberg University, Children's Hospital Medical Center, Cincinnati | Cerebral Ischemia | 12/24 | 12/24 | | |
| Completed | 2/3 | 438 | Europe, US | Intravenous glenzocimab (ACT017) 1000 mg, Thrombolysis +/- thrombectomy, Intravenous Placebo | Acticor Biotech, ACTICOR BIOTECH | Acute Ischemic Stroke | 04/24 | 04/24 | | |
Find-AF2, NCT04371055: Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study |
|
|
| Recruiting | N/A | 5200 | Europe | 7-day Holter ECG, Implantable cardiac monitor, Standard of care | University of Leipzig, Johannes Gutenberg University Mainz | Ischemic Stroke, Atrial Fibrillation | 06/26 | 12/26 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Not yet recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/26 | 05/31 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
